AJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, A. S.
Right arrow Articles by Brown, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, A. S.
Right arrow Articles by Brown, D. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?

Long-Term Outcome After Chemoembolization and Embolization of Hepatic Metastatic Lesions from Neuroendocrine Tumors

Alexander S. Ho1, Joel Picus2,3, Michael D. Darcy1,3, Benjamin Tan2,3, Jennifer E. Gould1,3, Thomas K. Pilgram1 and Daniel B. Brown1,3

1 Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd., Box 8131, Saint Louis, MO 63110.
2 Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO.
3 Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO.


Figure 1
View larger version (7K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 1A —Survival rates. Graph shows overall survival rate for entire group.

 

Figure 2
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 1B —Survival rates. Graph shows overall survival rates for carcinoid (black) and islet cell (gray) groups. Survival rates for subgroups are not significantly different.

 

Figure 3
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 2 —Graph shows progression-free survival time for carcinoid (black) and islet cell (gray) groups. Survival times for subgroups are not significantly different.

 

Figure 4
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 3 —Graph shows survival for entire patient group with (gray) and without (black) resection of primary tumor. Survival times for subgroups are not significantly different.

 

Figure 5
View larger version (9K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 4A —Survival times for patients with (gray) and without (black) extrahepatic metastasis at time of initial treatment. Graph shows survival time. Difference between group with and group without metastasis approached but did not reach statistical significance.

 

Figure 6
View larger version (8K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 4B —Survival times for patients with (gray) and without (black) extrahepatic metastasis at time of initial treatment. Graph shows progression-free survival rate. Difference between group with and group without metastasis was not significantly significant.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Roentgen Ray Society.